Todays tradesI'm not a trader...I am long on RVX and I do believe it is extremely undervalued.
I believe that smart money is buying in today.
- Regarding the adjustment yesterday I did not see any negative news about rvx-208 being released. So there may have been profit taking or something spooked the market.
- I believe, and there were good POVs yesterday on this, that RVX is grossly undervalued particularly for a drug moving into phase 3 trials with MACE as the primary endpoint because of it's cost to health care hhence high profile with the FDA.
- As each day and week passes there will be new knowledge gained from the Emerald Logic FACET predictive modelling about the efficacy and basic underlying biochemical pathways of why rvx-208, a BET inhibitor epigenetic molecule, that has clearly demonstrated many positive impacts such as increasing ApoA-I and functional HDL and most importantly reduced MACE (saving lives and improving the quality of lives).
- The Emerald FACIT predictive modelling will also be used with the FDA and with BP and also registering intellectual property that could be marketable.
- As each day passes we are moving closer to the FDA approval announcement.
- It would also be possible for RVX to use this information with the brokerage community. Unfortunately, even though the science is extremely solid, communications is one of the big holes at RVX. RVX has many successes and great stories to tell and yet they do not seem to be able to get the messages out and this is frustrating for me. Recently there have been hints that they may be trying to communicate but the effort seems feeble. Perhaps, if they are in the middle of a deal they are holding back on communications.
- With the presentations in February and the road shows this month they are getting the message out to the scientific and some investment communities.
- We know that AZ could use Crestor to patent partner with rvx-208 to the benefit of many diseases and to the huge benefit of AZ as their Crestor patents expire.
- We know that companies like Pfizer could come in and package rosuvastatin + rvx-208 and this would be a huge problem for AZ.
- We also know that RVX already has these patents!!!
Keep in mind, there is not just one market here. There are numerous patient populations and even it appeared that a CEPT drug is successful that does not, in any way, mean that there is not a huge market for rvx-208 and all it's epigenetic intellectual property developed over the past 15 years.
Five years ago what were the perceived odds? Now, moving into phase 3 the probabilities of success are much, much, much greater.
On a slightly different topic, there have been posts about a buyout of RVX and one of the posters said he did not want to see a buy out because he/she held shares in a company that was bought out and the sale price was 10% above the previous day or weeks share price. So he/she got little benefit while the company officers all received 5 year work out deals. I do not believe that this will occur at RVX simply because, even if the shares were trading at $10 there is
absolutely no way that Eastern (Ken Dart) nor NGN are going to sell their shares for $11...not a chance! And, even if the share were trading at $20 there is no way they will sell out at $22.
IMHO DYODD GLTA
ledrog, please keep the technical analysis coming. Jkj and GV please keep the excellent perspectives and digging coming. It is really valuable.
Good times and Easter (rebirth and resurrection) are coming!
Cheers
Toinv :)